{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004638","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.919181+00:00","generated_at":"2026-06-18T23:43:17.923182+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revolution Medicines reports FY2022 net loss $248.7M; cash $644.9M; provides clinical updates","bullets":["Net loss $248.7M for FY2022 vs $187.1M in 2021; Q4 net loss $56.5M.","Cash, equivalents and securities $644.9M as of Dec 31, 2022; expects to fund operations through 2024.","Revenue $35.4M in FY2022 includes $7.6M non-cash adjustment from Sanofi collaboration termination.","RMC-6236 shows early antitumor activity: 12 evaluable patients all stable or better, 10 with tumor reductions, 2 partial responses.","Sanofi terminates SHP2 collaboration effective June 2023; Revolution regains global rights to RMC-4630."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004638","json":"https://secwatch.observer/filing/0000950170-23-004638.json","markdown":"https://secwatch.observer/filing/0000950170-23-004638.md","text":"https://secwatch.observer/filing/0000950170-23-004638.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023004638/0000950170-23-004638-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023004638/rvmd-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:43:17.923182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ee8307a835e196a1f30fc6ad849497f383d3d57","claim":"Revolution Medicines, Inc. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On February 27, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023004638/0000950170-23-004638-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}